Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.

Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.

Item

http://www.wikidata.org/entity/Q44574133

Q44574133

about

Monitoring Allergen Immunotherapy Effects by Microarray Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future The expanding role of immunopharmacology: IUPHAR Review 16 New strategies for allergen T cell epitope identification: going beyond IgE Immunological mechanisms of allergen-specific immunotherapy Identification of critical amino acids in an immunodominant IgE epitope of Pen c 13, a major allergen from Penicillium citrinum A novel adjuvant-allergen complex, CBP-rFel d 1, induces up-regulation of CD86 expression and enhances cytokine release by human dendritic cells in vitro.Effect of activation of Toll-like receptor 7 in the inhibition of allergic asthma on a mouse model IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB.Nature of regulatory T cells in the context of allergic disease.Egg-white-specific IgA and IgA2 antibodies in egg-allergic children: is there a role in tolerance induction?Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy.Recombinant house dust mite allergens.Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy.Immune mechanisms of allergen-specific sublingual immunotherapy.Structural and immunologic cross-reactivity among filarial and mite tropomyosin: implications for the hygiene hypothesis.Effects of nasal corticosteroids on boosts of systemic allergen-specific IgE production induced by nasal allergen exposure The role of casein-specific IgA and TGF-β in children with food protein-induced enterocolitis syndrome to milk Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy.Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents.Allergy vaccines--new approaches to an old concept.Transition from a botanical to a molecular classification in tree pollen allergy: implications for diagnosis and therapy.Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials.Molecular approaches for new vaccines against allergy.Allergy testing: the role of recombinant allergens.IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy.Generation of hypoallergenic neoglycoconjugates for dendritic cell targeted vaccination: a novel tool for specific immunotherapy Sublingual immunotherapy of allergic diseases.Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine.Allergen immunotherapy for allergic respiratory diseases Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides Allergen-specific IgG antibodies purified from mite-allergic patients sera block the IgE recognition of Dermatophagoides pteronyssinus antigens: an in vitro study.Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy Optimized subunit vaccine protects against experimental leishmaniasis.How safe are the biologicals in treating asthma and rhinitis?The influence of antigen targeting to sub-cellular compartments on the anti-allergic potential of a DNA vaccine.Mechanisms of sublingual immunotherapy.A B Cell Epitope Peptide Derived from the Major Grass Pollen Allergen Phl p 1 Boosts Allergen-Specific Secondary Antibody Responses without Allergen-Specific T Cell Help.An immunological overview of allergen specific immunotherapy -- subcutaneous and sublingual routes.

P2860

Q26743503-3004C134-B344-4AA0-BC58-B01A7FCCC65D Q26768511-6706CAF7-532F-4463-8745-4281450B4DB1 Q26801862-4A3C1C7D-90F2-4010-8B0D-B4F0B812EE51 Q26824787-BFCD8C23-01E2-47C8-B089-EF358E626827 Q28265326-6BB938EC-BC8B-4EFD-A355-9AFE6552ECEF Q28482224-B2DFA433-DF26-4218-9753-D3E2B783D88C Q30768718-A4F49DAF-F324-463E-BA22-8C7EEE1103F2 Q33733105-A56E9108-4C3F-41E9-9105-6FB788DFBE63 Q33770788-531B7344-3AD3-4FDC-9865-0FFAB0DD4131 Q33846653-04B82463-AA83-4F11-AD91-D259BBA98C7F Q34051852-3116D317-4093-460C-A435-C6715183AE87 Q34166561-EF5841B4-37EC-4D08-BF05-38CFEE0538AE Q34361546-65254820-ABA8-4A89-925A-6779E2C27C02 Q34430399-78C3CED8-0632-4300-A26C-DB6DDE01F559 Q34484071-C83EF01E-5648-4F3A-9F0E-1BFF8F04BF36 Q34787526-5421892A-013A-41AF-92B1-FA4026C1F237 Q35113146-325C5D2B-5ABA-4B23-BBF7-998B3A506DE7 Q35146543-CBD92176-B161-4E85-BB12-D5383A2BE382 Q35558343-36DA3F6B-18D3-4F13-B5B2-D7CBFE9F7856 Q35566610-6C19A52B-6662-4269-9A17-E19D1F9C0E9E Q35842681-2FAC5441-31FB-4D0D-B7BC-EB507E544DE7 Q35873779-A8906957-2D9A-425C-B5BE-A3754A52D99A Q35975564-E927B99E-E095-4D9F-99C1-242E74C91E9B Q36302500-0568DA7D-6436-4476-84FA-47636AD7EE49 Q36383819-49D4ACA2-E201-4181-95F7-AB220C30E7F9 Q36395501-CB7EA0E1-67D3-4235-A3FB-8746DBC8C814 Q36545702-0CB29B5E-333E-45F5-9C3C-77960D87245B Q36549691-8B9D8046-F6B8-4C22-9C18-52660A7693D0 Q36583727-5757AAC9-C782-461A-9356-C86960C68E1A Q36689005-0F2922AF-C8C3-42F4-93D1-F09834A7785D Q36864947-A829ABB8-B522-475C-BB90-FE6259FD3477 Q36901292-D1169113-6EE3-44B1-932D-55401F09A93A Q37166041-49A430DC-8712-4311-A1BD-6835B785DBAC Q37309704-A7C12E38-AC26-407C-937D-5ACC7B0A9707 Q37439440-D200A3BF-403A-444F-820A-3D447563C27A Q37479670-BD239B40-9533-44F8-8BE8-7066D19FAA08 Q37502385-C4043B30-C1EB-4C03-A38C-46B119D95B66 Q37502904-91F155B4-E32E-42D3-AD56-ED7F627EEDD0 Q37625474-9192C7C8-B68C-417F-A088-8BD1EA1777A3 Q37625553-ED4CC14B-0B87-4CFC-9020-8A0A9BAE6BE4

P2860

Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.

Item

http://www.wikidata.org/entity/Q44574133

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Allergen-specific immunotherap ...... y-induced blocking antibodies.

@en

Allergen-specific immunotherap ...... y-induced blocking antibodies.

@nl

type

Item

label

Allergen-specific immunotherap ...... y-induced blocking antibodies.

@en

Allergen-specific immunotherap ...... y-induced blocking antibodies.

@nl

prefLabel

Allergen-specific immunotherap ...... y-induced blocking antibodies.

@en

Allergen-specific immunotherap ...... y-induced blocking antibodies.

@nl

P1476

Allergen-specific immunotherap ...... py-induced blocking antibodies

@en

P2093

D Kraft

http://www.w3.org/2001/XMLSchema#string

H Semper

http://www.w3.org/2001/XMLSchema#string

K J Drachenberg

http://www.w3.org/2001/XMLSchema#string

M Heinzkill

http://www.w3.org/2001/XMLSchema#string

M T Krauth

http://www.w3.org/2001/XMLSchema#string

N Mothes

http://www.w3.org/2001/XMLSchema#string

R Valenta

http://www.w3.org/2001/XMLSchema#string

V Niederberger

http://www.w3.org/2001/XMLSchema#string

W R Sperr

http://www.w3.org/2001/XMLSchema#string

Y Majlesi

http://www.w3.org/2001/XMLSchema#string

P2860

A human monoclonal IgE antibody defines a highly allergenic fragment of the major timothy grass pollen allergen, Phl p 5: molecular, immunological, and structural characterization of the epitope-containing domain.

Immunological mechanisms operative in allergen-specific immunotherapy.

The Th1/Th2 paradigm.

Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes.

A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections.

A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines.

Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction.

PROPHYLACTIC INOCULATION AGAINST HAY FEVER

P304

1198-1208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2222.2003.01699.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Peter Valent

P577

2003-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12956739

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

antibody

Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.

about

P2860

P2860

Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921